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World Kidney Day, 11 March 2010:  
we must act on diabetic kidney disease
In 2003, the International Society of Nephrol-
ogy and the International Diabetes Federation 
launched a booklet called Diabetes and Kidney 
Disease: Time to Act1 to highlight the global 
pandemic of type 2 diabetes and diabetic kidney 
disease. It aimed to alert governments, health 
organizations, providers, doctors, and patients 
to the increasing health and socioeconomic 
problems due to diabetic kidney disease and its 
sequelae, end-stage kidney disease requiring 
dialysis and cardiovascular death. Seven years 
later, the same message has become even more 
urgent. World Kidney Day 2010, under the aus-
pices of the International Society of Nephrology 
(ISN) and the International Federation of Kidney 
Foundations (IFKF), together with the Intern-
ational Diabetes Federation (IDF), provides yet 
another chance to underline the importance of 
diabetic kidney disease, stress its lack of aware-
ness at both public and governmental levels, and 
emphasize that its management involves preven-
tion, recognition, and treatment of its complica-
tions. Primary prevention of type 2 diabetes will 
require massive lifestyle changes in the develop-
ing and developed world supported by strong 
governmental commitment to promote lifestyle 
and societal change.
The global threat of type 2 diabetes
The 21st century has the most diabetogenic envi-
ronment in human history.2,3 Over the past 25 
years or so, the prevalence of type 2 diabetes in 
the United States has almost doubled, with three- 
to fivefold increases in India, Indonesia, China, 
Korea, and Thailand.4 In 2007, there were 246 
million people with diabetes in the world, but by 
2025, that number is estimated to reach 380 mil-
lion.5 People with impaired glucose tolerance, a 
‘prediabetic state,’ numbered 308 million in 2007, 
and this will increase to 418 million by 2025.5 The 
increase in prevalence of diabetes will be greater 
in developing countries. In Mexico, for example, 
18% of the adult population will have type 2 dia-
betes by 2025. According to the WHO (World 
Health Organization), China and India will have 
about 130 million diabetics by 2025; they will 
consume about 40% of their countries’ health-
care budget in addition to reducing productivity 
and hindering economic growth.
It was against this background that on 21 
December 2006, the United Nations General 
Assembly unanimously passed Resolution 61/225 
declaring diabetes an international public-health 
issue and identifying World Diabetes Day as a 
United Nations Day—only the second disease 
(after HIV/AIDS) to attain that status. For the 
first time, governments have acknowledged that 
a noninfectious disease poses as serious a threat 
to world health as infectious diseases such as 
HIV/AIDS, tuberculosis, and malaria. The prob-
lems of diabetes are now seen as a major global 
public-health concern, especially in the develop-
ing world, which can least afford it. The first step 
to acting on diabetic kidney disease must encom-
pass public-health campaigns aimed at preventing 
the development of type 2 diabetes.
Diabetic kidney disease
Diabetes is now the major cause of end-stage kid-
ney failure throughout the world in both devel-
oped and emerging nations.6 It is the primary 
diagnosis causing kidney disease in 20%–40% of 
people starting treatment for end-stage renal dis-
ease worldwide.7 In Australia, the number of new 
type 2 diabetes patients starting dialysis increased 
fivefold between 1993 and 2007.8 Between 1983 
and 2005, there was a sevenfold increase in the 
number of new patients starting renal replace-
ment therapy in Japan because of diabetes, 
accounting for 40% of all new-incidence patients.9 
Thus, some 30% of the predicted US$1.1 trillion 
medical costs of dialysis worldwide during this 
decade will result from diabetic nephropathy.10
In the United Kingdom Prospective Diabetes 
Study (UKPDS), the rates of progression of newly 
diagnosed type 2 diabetics between the stages of 
normoalbuminuria, microalbuminuria, macro-
albuminuria, and renal failure were 2%–3% per 
year.11 Over a median of 15 years of follow-up of 
4000 participants, almost 40% developed micro-
albuminuria.12 In the DEMAND study of 32,208 
people from 33 countries with known type 2 
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diabetes attending their family doctor, 39% had 
microalbuminuria, and prevalence increased with 
age, duration of diabetes, and presence of hyper-
tension.13 About 30% of the UKPDS cohort devel-
oped renal impairment, of whom almost 50% 
did not have preceding albuminuria.12 Reduced 
glomerular filtration rate and albuminuria caused 
by diabetic nephropathy are independent risk 
factors for cardiovascular events and death.14 
Therefore, a strategy to detect early diabetic kid-
ney disease by screening for albuminuria as well 
as reduced glomerular filtration rate is the second 
step in taking action on diabetic kidney disease.
An added difficulty to overcome is the remark-
able lack of awareness among patients about 
their condition. In population-based surveys, 
for every known diabetic patient, there is at least 
one more who is undiagnosed;15 only 8.7% of the 
general population were able to identify diabe-
tes as a risk factor for kidney disease.16 Very few 
patients with diabetic kidney disease are aware 
of their condition; some community surveys put 
patients’ awareness of their disease as low as 9.4%, 
particularly among those with milder impair-
ment.17 Thus, public education is the third step 
required for acting on diabetic kidney disease in 
the community. The IFKF has a long-term goal 
for all kidney patients worldwide not only to be 
aware of their disease, but to actively know, for 
example, their blood pressure and the treatment 
objectives.
Management of diabetic kidney disease
There is little use in screening populations or 
at-risk groups unless follow-up is undertaken 
and effective treatment is begun and assessed.18 
Fortunately, there is evidence that early therap-
eutic intervention in patients with chronic kidney 
disease or diabetes can delay onset of compli-
cations and improve outcomes. For example, 
the UKPDS,19,20 STENO-2,21 and ADVANCE 
studies22–24 all demonstrated that tight control 
of blood glucose level and blood pressure (and 
lipids in STENO-2) significantly reduced inci-
dence and progression of diabetic kidney disease. 
In people with type 2 diabetes, inhibition of the 
renin–angiotensin–aldosterone system using 
an angiotensin-converting enzyme inhibitor or 
an angiotensin receptor blocker decreased the 
progression from normoalbuminuria to micro-
albuminuria,25 reduced the progression from 
microalbuminuria to macroalbuminuria,26 and 
slowed the development of end-stage renal dis-
ease.27 Thus the use of an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker 
is now standard therapy for patients with diabetic 
nephropathy as well as glucose, lipid, and blood 
pressure control. Effective management using 
evidence-based therapies is the fourth step in 
tackling diabetic kidney disease.
The fifth step is the development of new thera-
pies. Many new agents are now in clinical trials 
to reduce renal damage and fibrosis, including 
agents that block formation of advanced glyca-
tion end products and other signaling pathways. 
Other novel agents may prove to be effective in 
large randomized double-blind clinical trials.28
How can we act now?
The steps to be taken are clear: campaigns aimed 
at (1) preventing type 2 diabetes, (2) screening 
for early diabetic kidney disease, (3) increasing 
patient awareness of kidney disease, (4) using 
medications of proven efficacy, and, finally, (5) 
researching and assessing new therapies. The 
ultimate challenge is to get action from primary 
health care to all higher levels; from the indi-
vidual patient to those at risk, in various health 
jurisdictions, in all countries, despite varying 
economic circumstances and priorities. The 
problem is a global one and yet requires action 
at a local level—prevention screening and treat-
ment strategies; education, including increasing 
awareness in both diabetic patients and those at 
risk of developing diabetes; and the establishment 
of diabetic kidney disease as a health priority by 
governments. Basic research and clinical trials 
searching for a new understanding and therapies 
must be supported.
The United Nations, as is noted above, recog-
nized the importance of diabetes by establishing a 
World Diabetes Day in 2006. Both the ISN and the 
IDF are working closely with the WHO to provide 
increasing understanding of the challenge that 
diabetic kidney disease poses to world health and 
health-care budgets. However, World Kidney Day 
also provides a focus for other international agen-
cies, government ministries of health, nongovern-
mental organizations, foundations, and academic 
institutions to come together with national kidney 
foundations to be involved in the effort to prevent 
and manage diabetic kidney disease.
The ISN, through its Commission for the Glo-
bal Advancement of Nephrology (COMGAN) 
Research and Prevention Committee, has devel-
oped a Web-based program, the KHDC (Program 
for Detection and Management of Chronic Kid-
ney Disease, Hypertension, Diabetes and Cardio-
vascular Disease in Developing Countries; http://
www.nature.com/isn/education/guidelines/isn/
pdf/ed_051027_2x1.pdf), as a global template 
involving a detection management and data 
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assessment program that has so far screened some 
42,000 people in 25 developing countries. The 
data are being stored and analyzed at the Kidney 
Disease Data Center at the committee headquar-
ters at the Mario Negri Institute in Bergamo, Italy. 
This program can be tailored to any individual 
country’s needs and resources. The IFKF also 
has a program initiated by the National Kidney 
Foundation in the United States called the Kidney 
Early Evaluation Program (KEEP), a screening 
program for people at high risk of kidney disease. 
KEEP has now been implemented in many coun-
tries and will again screen and manage patients 
with diabetic kidney disease.
The focus on diabetic kidney disease for World 
Kidney Day 2010 brings awareness of the mag-
nitude of the problem and its ramifications for 
global health for people with diabetes and kidney 
disease. It is therefore time to act, and act urgently. 
It is time for strategies that prevent diabetes and 
its sequelae. It is time for programs for health-
care workers to diagnose and treat people with 
diabetic kidney disease. It is time for governments 
to pass legislation to enable the diabetes pan-
demic to be controlled. After all, diabetic kidney 
disease, like the epidemics of infectious diseases 
that have long dominated public-health agendas, 
is potentially preventable. Indeed, 11 March 2010 
is the time to act on diabetic kidney disease, and 
to commit to sustaining that action long after 
World Kidney Day.
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